Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.71
-2.3%
$1.70
$1.40
$7.88
$75.91M1.56338,723 shs35,978 shs
Humanigen, Inc. stock logo
HGEN
Humanigen
$0.00
$0.00
$0.24
$24K-1.043.26 million shs2.06 million shs
MannKind Corporation stock logo
MNKD
MannKind
$3.77
-0.8%
$4.13
$3.51
$7.63
$1.15B0.962.25 million shs1.82 million shs
Prothena Corporation plc stock logo
PRTA
Prothena
$6.40
-2.6%
$6.17
$4.32
$25.42
$344.49M0.01801,177 shs569,047 shs
Veru Inc. stock logo
VERU
Veru
$0.60
+3.0%
$0.57
$0.45
$1.42
$88.02M-0.751.93 million shs1.56 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
+2.34%+0.86%+2.34%+10.76%-66.60%
Humanigen, Inc. stock logo
HGEN
Humanigen
0.00%0.00%0.00%0.00%0.00%
MannKind Corporation stock logo
MNKD
MannKind
-0.52%+5.41%-3.06%-18.45%-31.28%
Prothena Corporation plc stock logo
PRTA
Prothena
-0.15%+1.55%+24.90%-35.71%-68.73%
Veru Inc. stock logo
VERU
Veru
+5.37%-2.80%-12.79%+7.46%-33.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.3722 of 5 stars
2.02.00.00.00.62.51.3
Humanigen, Inc. stock logo
HGEN
Humanigen
N/AN/AN/AN/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
2.2638 of 5 stars
3.60.00.00.00.51.71.9
Prothena Corporation plc stock logo
PRTA
Prothena
3.56 of 5 stars
4.24.00.00.01.01.71.3
Veru Inc. stock logo
VERU
Veru
2.2133 of 5 stars
3.54.00.00.00.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0016.96% Upside
Humanigen, Inc. stock logo
HGEN
Humanigen
0.00
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.33174.09% Upside
Prothena Corporation plc stock logo
PRTA
Prothena
2.33
Hold$31.50392.19% Upside
Veru Inc. stock logo
VERU
Veru
3.00
Buy$4.00566.11% Upside

Current Analyst Ratings Breakdown

Latest EPIX, PRTA, VERU, HGEN, and MNKD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/28/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underperform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $14.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $18.00
5/13/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
Humanigen, Inc. stock logo
HGEN
Humanigen
$1.70M0.00N/AN/A($0.45) per share0.00
MannKind Corporation stock logo
MNKD
MannKind
$285.50M4.01$0.14 per share27.52($0.29) per share-13.00
Prothena Corporation plc stock logo
PRTA
Prothena
$137.94M2.50N/AN/A$9.05 per share0.71
Veru Inc. stock logo
VERU
Veru
$16.89M5.21N/AN/A$0.22 per share2.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)
Humanigen, Inc. stock logo
HGEN
Humanigen
-$70.73MN/A0.00N/AN/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1037.7016.39N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
Prothena Corporation plc stock logo
PRTA
Prothena
-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)
Veru Inc. stock logo
VERU
Veru
-$37.80M-$0.24N/AN/AN/AN/A-128.51%-76.51%8/6/2025 (Estimated)

Latest EPIX, PRTA, VERU, HGEN, and MNKD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04N/AN/AN/A$77.82 millionN/A
8/4/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.2430N/AN/AN/AN/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/8/2025Q1 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
5/8/2025Q2 2025
Veru Inc. stock logo
VERU
Veru
-$0.06-$0.05+$0.01-$0.05$0.73 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Humanigen, Inc. stock logo
HGEN
Humanigen
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15
Humanigen, Inc. stock logo
HGEN
Humanigen
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
9.00
9.00
Veru Inc. stock logo
VERU
Veru
N/A
3.80
3.80

Institutional Ownership

CompanyInstitutional Ownership
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Humanigen, Inc. stock logo
HGEN
Humanigen
4.55%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Prothena Corporation plc stock logo
PRTA
Prothena
97.08%
Veru Inc. stock logo
VERU
Veru
47.16%

Insider Ownership

CompanyInsider Ownership
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Humanigen, Inc. stock logo
HGEN
Humanigen
21.70%
MannKind Corporation stock logo
MNKD
MannKind
2.70%
Prothena Corporation plc stock logo
PRTA
Prothena
9.20%
Veru Inc. stock logo
VERU
Veru
15.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Humanigen, Inc. stock logo
HGEN
Humanigen
6119.08 million93.24 millionNo Data
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million295.73 millionOptionable
Prothena Corporation plc stock logo
PRTA
Prothena
13053.83 million48.88 millionOptionable
Veru Inc. stock logo
VERU
Veru
230146.58 million124.30 millionOptionable

Recent News About These Companies

Veru And Two Other Penny Stocks To Consider
Veru Inc (FMW.DU)
One Veru Insider Raised Stake By 150% In Previous Year
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.72 -0.03 (-1.71%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Humanigen stock logo

Humanigen NASDAQ:HGEN

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.77 -0.03 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$3.78 +0.01 (+0.27%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Prothena stock logo

Prothena NASDAQ:PRTA

$6.40 -0.17 (-2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$6.39 -0.01 (-0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Veru stock logo

Veru NASDAQ:VERU

$0.60 +0.02 (+2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$0.60 0.00 (-0.75%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.